- Previous Close
6.58 - Open
6.28 - Bid --
- Ask --
- Day's Range
5.78 - 6.32 - 52 Week Range
4.11 - 28.68 - Volume
8,632 - Avg. Volume
39,751 - Market Cap (intraday)
38.7M - Beta (5Y Monthly) 2.86
- PE Ratio (TTM)
-- - EPS (TTM)
-12.17 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
59.00
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
www.fortebiorx.comRecent News: FBRX
View MorePerformance Overview: FBRX
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FBRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FBRX
View MoreValuation Measures
Market Cap
39.62M
Enterprise Value
-18.74M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.75
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-45.51%
Return on Equity (ttm)
-80.82%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-35.48M
Diluted EPS (ttm)
-12.17
Balance Sheet and Cash Flow
Total Cash (mrq)
58.37M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-16.14M